TRIM26 inhibits clear cell renal cell carcinoma progression through destabilizing ETK and thus inactivation of AKT/mTOR signaling.

Di ZhengJinzhuo NingHao DengYuan RuanFan Cheng

Published in: Journal of translational medicine (2024)

Our results have shown a novel mechanism by which TRIM26 hinders the advancement of ccRCC by binding to and destabilizing ETK, thus leading to the deactivation of AKT/mTOR signaling. TRIM26 shows promise as both a therapeutic target and prognostic biomarker for ccRCC patients.

Keyphrases

cell proliferation
end stage renal disease
signaling pathway
ejection fraction
chronic kidney disease
peritoneal dialysis
big data
machine learning